SCD and metabolic dysfunction-associated steatotic liver disease: In one trial, the SCD-1 inhibitor Aramchol (developed by Galmed, Israel) decreased liver fat content in individuals with NAFLD at a dose of 300 mg but not 100 mg, compared with placebo, but no significant change was observed in ALT, adiponectin or HOMA-IR [126].